Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin for Insulin Resistance in Breast Cancer Survivors
NCT06763328Phase 3Recruiting
- Sponsor
- City of Hope
- Start
- Jan 2025
- Primary completion
- Jun 2031
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of liquid metformin (Aspargo Labs) in insulin resistance (IR), sponsored by City of Hope. Started Jan 2025; status: recruiting.
02
Drugs
liquid metformin (Aspargo Labs)
03
Conditions
insulin resistance (IR)
Beyond the preview
Go deeper on NCT06763328.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06763328.